Trinity Life Sciences Acquires Vancery’s Customer Research Technology

Asset Acquisition Enables Trinity to Better Connect with Healthcare Professionals

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announced it signed an asset purchase agreement for the acquisition of Vancery’s customer research technology. The investment expands Trinity’s insights and analytics product offerings, allowing the company to better connect with healthcare professionals to inform commercial strategy for its clients. The new technology will improve primary market research in the life sciences by integrating advanced research methods with an enhanced respondent experience to drive higher quality insights.

“We are thrilled to bring the sophisticated customer research technology that Vancery built to the healthcare space,” said Aparna Deshpande, PhD, Senior Partner, Insights. “Now, more than ever, payer, patient and healthcare provider research are critical in making sure treatments are available ASAP to those in need.”

Besides the technology acquisition, a team of experts from Vancery will join Trinity to continue to support and transform the software for use in healthcare.

“I am so proud of what the Vancery team has built and delighted that Trinity will bring our technology and vision to the next level,” said Gunnar Gregory, CEO, Vancery. “With Trinity, our unique technologies will help incorporate qualitative and quantitative research into their life science clients’ daily decision-making.”

About Trinity Life Sciences

Trinity Life Sciences is a trusted strategic commercialization partner, providing evidence-based solutions for the life sciences. With over 25 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity revolutionizing the commercial model, visit


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.